HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

luzindole

melatonin receptor antagonist; structure given in first source

Also Known As:

2-benzyl-N-acetyltryptamine; N 0774; N-0774; Acetamide, N-(2-(2-(phenylmethyl)-1H-indol-3-yl)ethyl)-

Networked: 51 relevant articles (3 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Biogenic Amines: 992
    - Biogenic Monoamines: 29
      - Tryptamines: 1679
        luzindole: 51
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Tryptamines: 1679
        luzindole: 51

Experts

1.	Mathes, Alexander M: 4 articles (01/2014 - 01/2008)
2.	Rensing, Hauke: 4 articles (01/2014 - 01/2008)
3.	Wolf, Beate: 4 articles (01/2014 - 01/2008)
4.	Reiter, Russel J: 3 articles (01/2020 - 10/2010)
5.	Laudon, Moshe: 3 articles (05/2016 - 02/2014)
6.	Kubulus, Darius: 3 articles (10/2008 - 01/2008)
7.	Weiler, Julia: 3 articles (10/2008 - 01/2008)
8.	Cai, Benzhi: 2 articles (10/2017 - 05/2017)
9.	Ding, Fengzhi: 2 articles (10/2017 - 05/2017)
10.	Feng, Chao: 2 articles (10/2017 - 05/2017)

Related Diseases

1.	Shock 01/01/2008 - "Melatonin receptor antagonist luzindole (LZN; 2.5 mg kg(-1)) almost completely abolished the protective effects of MEL pretreatment with respect to liver function (MEL + LZN/shock PDR(ICG), 7.31% min(-1) +/- 3.4 SD). " 10/01/2008 - "At the end of shock, animals were treated with ramelteon (1.0 mg/kg intravenously), melatonin receptor antagonist luzindole plus ramelteon (each 1.0 mg/kg intravenously), or vehicle. " 01/01/2008 - "At the end of shock, animals were treated with either melatonin (10 mg/kg, intravenously), melatonin receptor antagonist luzindole (2.5 mg/kg, intravenously) plus melatonin (10 mg/kg, intravenously), luzindole alone (2.5 mg/kg, intravenously), or vehicle. "
2.	Iron Overload 10/01/2017 - "In addition, protective effects of melatonin on iron overload-induced dysfunction of BMSCs were abolished by its inhibitor luzindole. "
3.	Sleep Wake Disorders 02/01/2021 - "Melatonin showed significant efficacy for ameliorating the sleep disorder and restoring physiological sleep, and most of the beneficial effect of melatonin was antagonized by luzindole, a melatonin receptor antagonist."
4.	Ulcer 05/01/2016 - "Luzindole, a MT receptor antagonist, did not inhibit the anti-inflammatory effect of melatonin (macroscopic score 1.12 ± 0.22, ulcer score 0.50 ± 0.16); however, luzindole increased MPO activity (7.57 ± 1.05). " 04/01/2002 - "In this study we compared the effects of intragastric (i.g.) administration of melatonin and its precursor, L-tryptophan, with or without concurrent treatment with luzindole, a selective antagonist of melatonin MT2 receptors, on healing of chronic gastric ulcers induced by serosal application of acetic acid (ulcer area 28 mm2). " 01/01/2014 - "Blockade of MT2 receptors by luzindole, significantly attenuated melatonin- and L-tryptophan-induced protection and increased the speed of ulcer healing and these effects were accompanied by an increase in the GBF and luminal content of NO suggesting that melatonin exhibits gastroprotection and hyperemia via activation of MT2 receptors and release of NO. The accumulated evidence indicates that the melatonin-induced gastroprotection and the enhancement in healing rate of gastric ulcers may involve the gastroprotective factors derived from the activation of PG/COX and NO/NOS systems as well as gastrin which also was shown to exhibit protective and trophic effects in the upper GItract. " 12/01/2009 - "Treatment with luzindole, an antagonist of Mel(2) receptors, or with L-NNA, the NO-synthase inhibitor, significantly attenuated melatonin- and L-tryptophan-induced protection and the acceleration of ulcer healing and the accompanying increase in the GBF and luminal content of NO. We conclude that 1) exogenous melatonin and that released from the L-tryptophan attenuate lesions induced by topical irritant such as ethanol and WRS via interaction with MT(2) receptors and due to an enhancement of gastric microcirculation, probably mediated by NO and PG derived from cNOS, iNOS and COX-2 overexpression and activity, and 2) the pineal gland plays an important role in the limitation of WRS-induced gastric lesions and acceleration of ulcer healing via releasing melatonin predominately at night time, that exerts gastroprotective and ulcer healing actions."
5.	Stomach Ulcer (Gastric Ulcer) 02/01/2005 - "Luzindole (MT(2) receptor antagonist) was given at a dose of 0.25 mg/kg intraperitoneally 30 min before and 6 and 18 h following the induction of colitis with acetic acid or gastric ulcer with ethanol. " 04/01/2002 - "In this study we compared the effects of intragastric (i.g.) administration of melatonin and its precursor, L-tryptophan, with or without concurrent treatment with luzindole, a selective antagonist of melatonin MT2 receptors, on healing of chronic gastric ulcers induced by serosal application of acetic acid (ulcer area 28 mm2). " 01/01/2014 - "Blockade of MT2 receptors by luzindole, significantly attenuated melatonin- and L-tryptophan-induced protection and increased the speed of ulcer healing and these effects were accompanied by an increase in the GBF and luminal content of NO suggesting that melatonin exhibits gastroprotection and hyperemia via activation of MT2 receptors and release of NO. The accumulated evidence indicates that the melatonin-induced gastroprotection and the enhancement in healing rate of gastric ulcers may involve the gastroprotective factors derived from the activation of PG/COX and NO/NOS systems as well as gastrin which also was shown to exhibit protective and trophic effects in the upper GItract. "

Related Drugs and Biologics

1.	Melatonin
2.	Melatonin Receptors (Melatonin Receptor)
3.	Tryptophan (L-Tryptophan)
4.	Acetic Acid (Vinegar)
5.	Heme Oxygenase-1
6.	Caspases
7.	Cytokines
8.	Serotonin Antagonists
9.	Methysergide (Sansert)
10.	Methylnitrosourea (N-Methyl-N-nitrosourea)

Related Therapies and Procedures

1.	Intraperitoneal Injections
2.	Intravenous Injections
3.	Injections
4.	Pinealectomy